TRVI Trevi Therapeutics, Inc.

Trevi Therapeutics has delivered very strong long term gains, yet the stock now screens as expensive on broad valuation checks. This raises questions about how much of the story is already in the price. The stock has returned roughly 10x over the past 5 years, which is an unusually large move that can leave less room for valuation mistakes. Upcoming presentations in 2026 on nalbuphine ER trial data may support confidence in the Trevi Therapeutics pipeline. Any disappointment in clinical...

Trevi Therapeutics (NASDAQ:TRVI) said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio, for multiple chronic-cough indications. President and Chief Executive Officer Jennifer Good said t

Trevi Therapeutics Inc (TRVI) reports progress in IPF and RCC trials, backed by $319 million in funding and a competitive edge following a rival's program exit.

Trevi Therapeutics grew its share prices by 9.85 percent on Friday to finish at $19.07 apiece, after management underscored strong clinical trial results from its treatment candidate for chronic cough. Speaking at a three-day conference in Europe, Trevi Therapeutics Inc (NASDAQ:TRVI) CEO Jennifer Good and Chief Development Officer James Cassella highlighted that the oral treatment […]